Dr. Rangachari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Shapiro 9
Boston, MA 02215Phone+1 617-667-2100Fax+1 617-667-2518
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2014- Johns Hopkins UniversityChief Residency, Internal Medicine, 2011 - 2012
- Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2007
Certifications & Licensure
MA State Medical License 2014 - 2025
MD State Medical License 2010 - 2015- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Publications & Presentations
PubMed
- Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions.Charlotte S Walmsley, Zachary Schoepflin, Charlotte De Brabandt, Deepa Rangachari, Shana Berwick
Blood Cells, Molecules & Diseases. 2025-02-01 - Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.Soravis Osataphan, Muhammad Awidi, Yu Jen Jan, Krishna Gunturu, Shriram Sundararaman
Lung Cancer. 2024-12-01 - 2 citationsPhase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.Catherine B Meador, Subba R Digumarthy, Beow Y Yeap, Yin P Hung, Mari Mino-Kenudson
Clinical Cancer Research. 2024-10-29
Press Mentions
Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/OncologistsDecember 20th, 2022- A First-of-Its-Kind Opportunity to Integrate Training in Medical Oncology, Hematology, and Palliative CareJune 10th, 2022
Anti-PD-1 Success in Advanced NSCLC PersistsOctober 8th, 2019- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
